A Phase II/ III trial evaluating safety and efficacy of Imigliptin Hydrochloride (KBP-3853).

Trial Profile

A Phase II/ III trial evaluating safety and efficacy of Imigliptin Hydrochloride (KBP-3853).

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 09 Sep 2016

At a glance

  • Drugs Imigliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Sep 2016 New trial record
    • 04 Aug 2016 According to a XuanZhu Pharma media release, this trial has been approved by CFDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top